ArticleQJM : monthly journal of the Association of Physicians2016
Candida growth in urine cultures: a contemporary analysis of species and antifungal susceptibility profiles.
Article in QJM : monthly journal of the Association of Physicians, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Species Distribution and Determinants ofMedicina (Kaunas, Lithuania) · 2026Article
- Candida urinary tract infections, antifungal susceptibility and factors associated with candiduria among pregnant women seeking antenatal care at Murang'a County Referral Hospital, Kenya.BMC pregnancy and childbirth · 2026Article
- The first prevalence and antifungal susceptibility profile of Candida infections in Palestine, 2022.BMC infectious diseases · 2024Article
- Non-Current medical mycology · 2021Article
- A New Gold Rush: A Review of Current and Developing Diagnostic Tools for Urinary Tract Infections.Diagnostics (Basel, Switzerland) · 2021Review
- Resensitization of Fluconazole-Resistant UrinaryPolish journal of microbiology · 2020Article
- Performance of yeast-like cell counting (YLCC) using the Sysmex UF-1000i for clinical candiduria screening.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Article
- Determination of antimicotic susceptibility pattern ofJournal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2019Article
- Vancomycin resistant enterococci in urine cultures: Antibiotic susceptibility trends over a decade at a tertiary hospital in the United Kingdom.Investigative and clinical urology · 2016Article
- Distribution and antifungal susceptibility ofTherapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent publications suggest the distribution of Candida species causing candiduria may vary geographically, which has implications for the continued efficacy of antifungal therapy and emerging resistance.
aimTo investigate the incidence of Candiduria at a university hospital in the UK. Further, to assess the distribution of species and the accompanying antifungal susceptibility profile, in order to monitor the clinical utility of current antifungal treatment guidelines for candiduria so that patients receive the best possible outcomes from the most up to date care.
designRetrospective audit.
methodsFrom 1st January 2005 to 31st October 2014, we retrospectively reviewed 37 538 positive urine cultures recorded in a computerized laboratory results database. Identification and susceptibility testing was performed using the VITEK® 2 fungal susceptibility card (bioMérieux, Marcy d'Etoile, France).
resultsIn total, 96 cultures were positive for Candida species, of which 69 (72%) were C.albicans, which translates to a prevalence of 2.6 per 1000 positive urine cultures. Candiduria was more common in younger patients, males and catheterized females. We report 94 and 73% of isolates of C.albicans and other non-C.albicans Candida species were susceptible to fluconazole. All isolates were susceptible to amphotericin B.
conclusionsOur results add weight to the evidence supporting current European and North American guidelines recommending fluconazole or amphotericin B for treatment of candiduria, if antifungal treatment is clinically indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.